News Archives - Page 20 of 44 - Imaging Endpoints

Clinical Endpoints Well-Positioned to Transition Treatments to Future Patients

April 6, 2021 - As researchers worldwide develop new therapies for diseases such as Alzheimer's, Donnell Carmichael, VP for Clinical Research Operations, says Clinical Endpoints is well-positioned to help transition these treatments to future patients. "Clinical Endpoints is introducing physicians… Read More

Registration Trials Help Improve Outlook for Prostate Cancer

April 2, 2021 - Through our work in supporting successful registration trials that are improving overall survival and radiographic progression-free survival in patients with prostate cancer, as well as our novel imaging techniques, we are joining and winning the fight… Read More

Imaging Endpoints Expands Research Services

Global Imaging Leader Formally Launches Research Endpoints March 31, 2021 - Scottsdale, Arizona – Imaging Endpoints (IE) announced today that it has formally established Research Endpoints, LLC, as a new wholly-owned subsidiary to manage the extraordinary demand for its exploratory… Read More

Novartis Announces Positive Result of Phase III Study With Radioligand Therapy ¹⁷⁷Lu-PSMA-617 in Patients With Advanced Prostate Cancer

Basel, March, 23, 2021 — Novartis has reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of ¹⁷⁷Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone.

Imaging Endpoints Continues Growth on Global Scale

March 18, 2021 - Imaging Endpoints is making an impact on a global scale – and we are nearing an announcement of new offices in both Switzerland and China. Our primary offices are in Scottsdale, AZ, and Walltham, MA, USA;… Read More